Use of Antihypertensives, Blood Pressure, and Estimated Risk of Dementia in Late Life

Matthew J. Lennon(UNSW Sydney), Ben C. P. Lam(La Trobe University), Darren M. Lipnicki(UNSW Sydney), John D. Crawford(UNSW Sydney), Ruth Peters(UNSW Sydney), Aletta E. Schutte(UNSW Sydney), Henry Brodaty(UNSW Sydney), Anbupalam Thalamuthu(UNSW Sydney), Therese Rydberg Sterner(Stockholm University), Jenna Najar(Sahlgrenska University Hospital), Ingmar Skoog(Sahlgrenska University Hospital), Steffi G. Riedel‐Heller(Leipzig University), Susanne Röhr(Trinity College Dublin), Alexander Pabst(Leipzig University), António Lobo(Universidad de Zaragoza), Concepción De‐la‐Cámara(Universidad de Zaragoza), Elena Lobo(Universidad de Zaragoza), Toyin Bello(University of Ibadan), Oye Gureje(University of Ibadan), Akin Ojagbemi(University of Ibadan), Richard B. Lipton(Albert Einstein College of Medicine), Mindy J. Katz(Albert Einstein College of Medicine), Carol A. Derby(Albert Einstein College of Medicine), Ki Woong Kim(Seoul National University), Ji Won Han(Seoul National University), Dae Jong Oh(Kangbuk Samsung Hospital), E Rolandi(University of Pavia), Annalisa Davin(Fondazione Golgi Cenci), Michele Rossi(Fondazione Golgi Cenci), Nikolaos Scarmeas(National and Kapodistrian University of Athens), Mary Yannakoulia(Harokopio University of Athens), Themis Dardiotis(University of Thessaly), Hugh C. Hendrie(Alzheimer’s Disease Neuroimaging Initiative), Sujuan Gao(Alzheimer’s Disease Neuroimaging Initiative), Isabelle Carrière(Institute for Neurosciences of Montpellier), Karen Ritchie(Institute for Neurosciences of Montpellier), Kaarin J. Anstey(UNSW Sydney), Nicolas Cherbuin(Australian National University), Shifu Xiao(Shanghai Jiao Tong University), Ling Yue(Shanghai Jiao Tong University), Wei Li(Shanghai Jiao Tong University), Maëlenn Guerchet(Institut d’Epidémiologie Neurologique et de Neurologie Tropicale), Pierre‐Marie Preux(Institut d’Epidémiologie Neurologique et de Neurologie Tropicale), Victor Aboyans(Institut d’Epidémiologie Neurologique et de Neurologie Tropicale), Mary N. Haan(University of California, San Francisco), Allison E. Aiello(Columbia University), Tze Pin Ng(Ministry of Health), Ma Shwe Zin Nyunt(National University of Singapore), Qi Gao(National University of Singapore), Márcia Scazufca(Universidade de São Paulo), Perminder S. Sachdev(UNSW Sydney)
JAMA Network Open
September 12, 2023
Cited by 94Open Access
Full Text

Abstract

Importance: The utility of antihypertensives and ideal blood pressure (BP) for dementia prevention in late life remains unclear and highly contested. Objectives: To assess the associations of hypertension history, antihypertensive use, and baseline measured BP in late life (age >60 years) with dementia and the moderating factors of age, sex, and racial group. Data Source and Study Selection: Longitudinal, population-based studies of aging participating in the Cohort Studies of Memory in an International Consortium (COSMIC) group were included. Participants were individuals without dementia at baseline aged 60 to 110 years and were based in 15 different countries (US, Brazil, Australia, China, Korea, Singapore, Central African Republic, Republic of Congo, Nigeria, Germany, Spain, Italy, France, Sweden, and Greece). Data Extraction and Synthesis: Participants were grouped in 3 categories based on previous diagnosis of hypertension and baseline antihypertensive use: healthy controls, treated hypertension, and untreated hypertension. Baseline systolic BP (SBP) and diastolic BP (DBP) were treated as continuous variables. Reporting followed the Preferred Reporting Items for Systematic Review and Meta-Analyses of Individual Participant Data reporting guidelines. Main Outcomes and Measures: The key outcome was all-cause dementia. Mixed-effects Cox proportional hazards models were used to assess the associations between the exposures and the key outcome variable. The association between dementia and baseline BP was modeled using nonlinear natural splines. The main analysis was a partially adjusted Cox proportional hazards model controlling for age, age squared, sex, education, racial group, and a random effect for study. Sensitivity analyses included a fully adjusted analysis, a restricted analysis of those individuals with more than 5 years of follow-up data, and models examining the moderating factors of age, sex, and racial group. Results: The analysis included 17 studies with 34 519 community dwelling older adults (20 160 [58.4%] female) with a mean (SD) age of 72.5 (7.5) years and a mean (SD) follow-up of 4.3 (4.3) years. In the main, partially adjusted analysis including 14 studies, individuals with untreated hypertension had a 42% increased risk of dementia compared with healthy controls (hazard ratio [HR], 1.42; 95% CI 1.15-1.76; P = .001) and 26% increased risk compared with individuals with treated hypertension (HR, 1.26; 95% CI, 1.03-1.53; P = .02). Individuals with treated hypertension had no significant increased dementia risk compared with healthy controls (HR, 1.13; 95% CI, 0.99-1.28; P = .07). The association of antihypertensive use or hypertension status with dementia did not vary with baseline BP. There was no significant association of baseline SBP or DBP with dementia risk in any of the analyses. There were no significant interactions with age, sex, or racial group for any of the analyses. Conclusions and Relevance: This individual patient data meta-analysis of longitudinal cohort studies found that antihypertensive use was associated with decreased dementia risk compared with individuals with untreated hypertension through all ages in late life. Individuals with treated hypertension had no increased risk of dementia compared with healthy controls.


Related Papers

No related papers found

Powered by citation graph analysis